| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graft Rejection | 31 | 2022 | 149 | 3.300 |
Why?
|
| Graft Survival | 28 | 2022 | 228 | 3.180 |
Why?
|
| Hindlimb | 13 | 2017 | 57 | 3.130 |
Why?
|
| Organ Transplantation | 9 | 2019 | 65 | 3.100 |
Why?
|
| Immunosuppression | 14 | 2019 | 80 | 2.430 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 7 | 2017 | 75 | 2.320 |
Why?
|
| Nanomedicine | 4 | 2020 | 17 | 2.200 |
Why?
|
| Adipose Tissue | 4 | 2019 | 330 | 1.950 |
Why?
|
| Reconstructive Surgical Procedures | 12 | 2018 | 190 | 1.860 |
Why?
|
| Upper Extremity | 6 | 2017 | 53 | 1.840 |
Why?
|
| Tacrolimus | 12 | 2022 | 44 | 1.830 |
Why?
|
| Immunosuppressive Agents | 21 | 2022 | 167 | 1.760 |
Why?
|
| Nerve Regeneration | 5 | 2018 | 40 | 1.530 |
Why?
|
| Eye | 2 | 2019 | 15 | 1.400 |
Why?
|
| Skin Transplantation | 6 | 2020 | 52 | 1.280 |
Why?
|
| Transplantation Tolerance | 8 | 2019 | 14 | 1.230 |
Why?
|
| Transplantation, Homologous | 24 | 2018 | 113 | 1.160 |
Why?
|
| T-Lymphocytes, Regulatory | 7 | 2020 | 33 | 1.140 |
Why?
|
| Animals | 48 | 2022 | 7328 | 1.090 |
Why?
|
| Bone Marrow Transplantation | 6 | 2017 | 65 | 0.980 |
Why?
|
| Rats | 23 | 2022 | 1607 | 0.880 |
Why?
|
| Peripheral Nerves | 3 | 2018 | 59 | 0.870 |
Why?
|
| Regenerative Medicine | 3 | 2019 | 192 | 0.810 |
Why?
|
| Mesenchymal Stem Cells | 3 | 2021 | 166 | 0.800 |
Why?
|
| Transplantation Immunology | 8 | 2020 | 27 | 0.800 |
Why?
|
| Humans | 55 | 2023 | 29449 | 0.750 |
Why?
|
| Rats, Inbred Lew | 10 | 2022 | 116 | 0.730 |
Why?
|
| Transplantation | 2 | 2019 | 12 | 0.730 |
Why?
|
| Adipogenesis | 1 | 2019 | 26 | 0.700 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2019 | 3 | 0.700 |
Why?
|
| Anesthesia | 2 | 2017 | 65 | 0.680 |
Why?
|
| Postoperative Complications | 8 | 2020 | 674 | 0.680 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2016 | 80 | 0.650 |
Why?
|
| Transplantation Chimera | 6 | 2017 | 21 | 0.640 |
Why?
|
| Tissue Engineering | 3 | 2019 | 617 | 0.620 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2023 | 83 | 0.600 |
Why?
|
| Facial Transplantation | 3 | 2016 | 8 | 0.590 |
Why?
|
| Perioperative Care | 1 | 2017 | 58 | 0.580 |
Why?
|
| Postoperative Care | 4 | 2017 | 73 | 0.580 |
Why?
|
| Chondroitin ABC Lyase | 1 | 2016 | 1 | 0.570 |
Why?
|
| Rats, Inbred BN | 7 | 2022 | 32 | 0.560 |
Why?
|
| Immunotherapy | 1 | 2017 | 71 | 0.560 |
Why?
|
| Tissue Donors | 8 | 2023 | 167 | 0.520 |
Why?
|
| Peroneal Nerve | 1 | 2015 | 15 | 0.520 |
Why?
|
| Veins | 1 | 2015 | 29 | 0.510 |
Why?
|
| Guided Tissue Regeneration | 1 | 2015 | 36 | 0.510 |
Why?
|
| Spine | 2 | 2011 | 38 | 0.500 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2015 | 104 | 0.500 |
Why?
|
| Hand Injuries | 3 | 2016 | 24 | 0.480 |
Why?
|
| Program Development | 2 | 2011 | 85 | 0.460 |
Why?
|
| Chimerism | 4 | 2023 | 4 | 0.460 |
Why?
|
| Male | 34 | 2020 | 17969 | 0.450 |
Why?
|
| Amputation, Traumatic | 2 | 2011 | 10 | 0.440 |
Why?
|
| Immune Tolerance | 7 | 2020 | 67 | 0.420 |
Why?
|
| Surgery Department, Hospital | 1 | 2011 | 7 | 0.410 |
Why?
|
| Cells, Cultured | 6 | 2017 | 802 | 0.400 |
Why?
|
| Adult Stem Cells | 1 | 2011 | 24 | 0.390 |
Why?
|
| Patient Care Planning | 1 | 2012 | 53 | 0.390 |
Why?
|
| Cell Separation | 1 | 2011 | 87 | 0.390 |
Why?
|
| Patient Selection | 2 | 2012 | 257 | 0.390 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2019 | 748 | 0.340 |
Why?
|
| Tissue and Organ Procurement | 2 | 2019 | 69 | 0.330 |
Why?
|
| Blepharoplasty | 1 | 2008 | 2 | 0.320 |
Why?
|
| Blinking | 1 | 2008 | 5 | 0.320 |
Why?
|
| Dry Eye Syndromes | 1 | 2008 | 3 | 0.320 |
Why?
|
| Keratomileusis, Laser In Situ | 1 | 2008 | 3 | 0.320 |
Why?
|
| Pulmonary Alveoli | 3 | 2013 | 19 | 0.320 |
Why?
|
| Transplantation, Autologous | 2 | 2019 | 78 | 0.300 |
Why?
|
| Graft vs Host Disease | 3 | 2004 | 18 | 0.300 |
Why?
|
| Feasibility Studies | 3 | 2020 | 269 | 0.300 |
Why?
|
| Models, Animal | 6 | 2019 | 161 | 0.300 |
Why?
|
| Macrophages | 2 | 2020 | 188 | 0.290 |
Why?
|
| Time Factors | 7 | 2019 | 2013 | 0.290 |
Why?
|
| Inflammation Mediators | 3 | 2020 | 101 | 0.280 |
Why?
|
| Swine | 7 | 2022 | 203 | 0.270 |
Why?
|
| Risk Assessment | 5 | 2019 | 1327 | 0.250 |
Why?
|
| Patient Care Team | 4 | 2012 | 124 | 0.230 |
Why?
|
| Tissue Transplantation | 3 | 2010 | 16 | 0.230 |
Why?
|
| Immunomodulation | 4 | 2020 | 30 | 0.220 |
Why?
|
| Surgical Flaps | 2 | 2015 | 69 | 0.220 |
Why?
|
| Cell Proliferation | 5 | 2017 | 574 | 0.220 |
Why?
|
| Bone Marrow Cells | 3 | 2011 | 115 | 0.220 |
Why?
|
| Treatment Outcome | 8 | 2020 | 3123 | 0.220 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 1221 | 0.210 |
Why?
|
| Organ Preservation | 2 | 2019 | 13 | 0.210 |
Why?
|
| Cadaver | 2 | 2011 | 145 | 0.200 |
Why?
|
| Neovascularization, Physiologic | 4 | 2018 | 106 | 0.200 |
Why?
|
| Drug Carriers | 2 | 2019 | 16 | 0.190 |
Why?
|
| Arm | 2 | 2012 | 31 | 0.190 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 533 | 0.190 |
Why?
|
| Forelimb | 2 | 2019 | 4 | 0.190 |
Why?
|
| Mice | 9 | 2020 | 2383 | 0.180 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2020 | 18 | 0.180 |
Why?
|
| Cell-Derived Microparticles | 1 | 2019 | 5 | 0.180 |
Why?
|
| Colloids | 1 | 2019 | 3 | 0.180 |
Why?
|
| Prodrugs | 1 | 2019 | 13 | 0.180 |
Why?
|
| Nanostructures | 1 | 2019 | 16 | 0.180 |
Why?
|
| Skin | 3 | 2013 | 205 | 0.180 |
Why?
|
| Drug Design | 1 | 2019 | 44 | 0.180 |
Why?
|
| Ethics, Medical | 3 | 2012 | 16 | 0.170 |
Why?
|
| Extracellular Matrix | 2 | 2018 | 226 | 0.170 |
Why?
|
| Confidentiality | 1 | 2019 | 22 | 0.170 |
Why?
|
| Hydrogen Sulfide | 1 | 2019 | 3 | 0.170 |
Why?
|
| Skin Physiological Phenomena | 1 | 2019 | 7 | 0.170 |
Why?
|
| Alloys | 1 | 2019 | 2 | 0.170 |
Why?
|
| Tissue Scaffolds | 2 | 2019 | 392 | 0.170 |
Why?
|
| Informed Consent | 1 | 2019 | 51 | 0.170 |
Why?
|
| Absorbable Implants | 1 | 2019 | 24 | 0.170 |
Why?
|
| Arteries | 1 | 2019 | 61 | 0.170 |
Why?
|
| Oxygen | 1 | 2019 | 139 | 0.170 |
Why?
|
| Bone Nails | 1 | 2019 | 29 | 0.170 |
Why?
|
| Waiting Lists | 1 | 2018 | 30 | 0.160 |
Why?
|
| Decanoates | 1 | 2018 | 2 | 0.160 |
Why?
|
| Glycerol | 1 | 2018 | 5 | 0.160 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2018 | 5 | 0.160 |
Why?
|
| Femoral Fractures | 1 | 2019 | 39 | 0.160 |
Why?
|
| Cytokines | 4 | 2020 | 243 | 0.160 |
Why?
|
| Mycophenolic Acid | 3 | 2019 | 28 | 0.160 |
Why?
|
| Ischemia | 1 | 2019 | 94 | 0.160 |
Why?
|
| Polymers | 1 | 2018 | 59 | 0.160 |
Why?
|
| Models, Theoretical | 1 | 2019 | 131 | 0.160 |
Why?
|
| Forearm | 3 | 2013 | 37 | 0.160 |
Why?
|
| Optic Nerve Injuries | 1 | 2017 | 2 | 0.160 |
Why?
|
| Carotid Arteries | 1 | 2018 | 97 | 0.160 |
Why?
|
| Interleukin-2 | 2 | 2015 | 33 | 0.160 |
Why?
|
| Reperfusion Injury | 1 | 2018 | 43 | 0.160 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2018 | 79 | 0.160 |
Why?
|
| Retinal Ganglion Cells | 1 | 2017 | 16 | 0.150 |
Why?
|
| Central Nervous System | 1 | 2017 | 29 | 0.150 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2017 | 29 | 0.150 |
Why?
|
| Principal Component Analysis | 1 | 2017 | 60 | 0.150 |
Why?
|
| Cell Survival | 3 | 2015 | 274 | 0.150 |
Why?
|
| Pain | 1 | 2020 | 283 | 0.150 |
Why?
|
| Blood Component Transfusion | 1 | 2017 | 10 | 0.150 |
Why?
|
| Microspheres | 1 | 2017 | 38 | 0.150 |
Why?
|
| Transducers | 1 | 2016 | 5 | 0.150 |
Why?
|
| Magnetics | 1 | 2016 | 5 | 0.150 |
Why?
|
| Nanoparticles | 1 | 2017 | 48 | 0.140 |
Why?
|
| Schwann Cells | 1 | 2016 | 5 | 0.140 |
Why?
|
| Image Enhancement | 1 | 2016 | 70 | 0.140 |
Why?
|
| Lymphocyte Activation | 1 | 2017 | 82 | 0.140 |
Why?
|
| Vascular Diseases | 1 | 2017 | 62 | 0.140 |
Why?
|
| Female | 14 | 2020 | 18341 | 0.140 |
Why?
|
| Inflammation | 1 | 2020 | 510 | 0.140 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2016 | 40 | 0.140 |
Why?
|
| Epigastric Arteries | 1 | 2015 | 1 | 0.140 |
Why?
|
| Dissection | 1 | 2015 | 16 | 0.140 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2015 | 27 | 0.140 |
Why?
|
| Acute Disease | 2 | 2019 | 239 | 0.140 |
Why?
|
| Desensitization, Immunologic | 1 | 2015 | 3 | 0.140 |
Why?
|
| Immunization | 1 | 2015 | 28 | 0.130 |
Why?
|
| Glucose | 1 | 2016 | 165 | 0.130 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2015 | 25 | 0.130 |
Why?
|
| Electrodiagnosis | 1 | 2015 | 36 | 0.130 |
Why?
|
| Mandibular Neoplasms | 1 | 2015 | 6 | 0.130 |
Why?
|
| Hydrogels | 3 | 2021 | 107 | 0.130 |
Why?
|
| Thigh | 1 | 2015 | 39 | 0.130 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 247 | 0.130 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2015 | 97 | 0.120 |
Why?
|
| Swine, Miniature | 3 | 2022 | 5 | 0.120 |
Why?
|
| Burns | 1 | 2015 | 98 | 0.120 |
Why?
|
| Bone Plates | 1 | 2015 | 68 | 0.120 |
Why?
|
| Drug Delivery Systems | 3 | 2020 | 93 | 0.120 |
Why?
|
| Lymphocyte Depletion | 2 | 2011 | 14 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 525 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 143 | 0.110 |
Why?
|
| Wnt Proteins | 1 | 2013 | 18 | 0.110 |
Why?
|
| Adult | 8 | 2018 | 8511 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 1 | 2015 | 118 | 0.110 |
Why?
|
| Bone Transplantation | 1 | 2013 | 47 | 0.110 |
Why?
|
| Heart Transplantation | 1 | 2013 | 26 | 0.110 |
Why?
|
| Drug Compounding | 1 | 2013 | 36 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 301 | 0.110 |
Why?
|
| Receptors, CXCR4 | 1 | 2012 | 11 | 0.110 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2012 | 13 | 0.110 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2012 | 4 | 0.110 |
Why?
|
| Karnofsky Performance Status | 1 | 2012 | 10 | 0.100 |
Why?
|
| Esthetics | 1 | 2012 | 11 | 0.100 |
Why?
|
| Personality | 1 | 2012 | 16 | 0.100 |
Why?
|
| Facial Injuries | 1 | 2012 | 13 | 0.100 |
Why?
|
| Langerhans Cells | 1 | 2011 | 1 | 0.100 |
Why?
|
| Psychological Tests | 1 | 2012 | 33 | 0.100 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2012 | 23 | 0.100 |
Why?
|
| Medical History Taking | 1 | 2012 | 32 | 0.100 |
Why?
|
| Potassium Channels, Tandem Pore Domain | 1 | 2011 | 1 | 0.100 |
Why?
|
| Public Relations | 1 | 2011 | 3 | 0.100 |
Why?
|
| Hyperoxia | 1 | 2011 | 3 | 0.100 |
Why?
|
| Rats, Inbred WF | 4 | 2004 | 8 | 0.100 |
Why?
|
| Face | 1 | 2012 | 25 | 0.100 |
Why?
|
| Edema | 1 | 2011 | 30 | 0.100 |
Why?
|
| Chondroitinases and Chondroitin Lyases | 1 | 2011 | 1 | 0.100 |
Why?
|
| Exanthema | 1 | 2011 | 21 | 0.100 |
Why?
|
| Erythema | 1 | 2011 | 27 | 0.100 |
Why?
|
| Wound Healing | 3 | 2019 | 186 | 0.100 |
Why?
|
| Dendritic Cells | 1 | 2011 | 61 | 0.100 |
Why?
|
| Sirolimus | 2 | 2022 | 35 | 0.100 |
Why?
|
| Cell Movement | 1 | 2012 | 161 | 0.100 |
Why?
|
| Epithelial Cells | 1 | 2012 | 140 | 0.100 |
Why?
|
| Motivation | 1 | 2012 | 104 | 0.100 |
Why?
|
| Adaptation, Psychological | 1 | 2012 | 126 | 0.100 |
Why?
|
| Glycosaminoglycans | 2 | 2018 | 20 | 0.090 |
Why?
|
| Cell Culture Techniques | 1 | 2011 | 165 | 0.090 |
Why?
|
| Social Support | 1 | 2012 | 165 | 0.090 |
Why?
|
| Attitude to Health | 1 | 2012 | 148 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2011 | 371 | 0.090 |
Why?
|
| Patient Compliance | 1 | 2012 | 213 | 0.090 |
Why?
|
| Medication Adherence | 1 | 2012 | 144 | 0.090 |
Why?
|
| Hyaluronic Acid | 2 | 2021 | 46 | 0.090 |
Why?
|
| Rats, Inbred ACI | 3 | 2004 | 5 | 0.090 |
Why?
|
| Health Status | 1 | 2012 | 371 | 0.090 |
Why?
|
| Antibodies, Neoplasm | 1 | 2009 | 12 | 0.090 |
Why?
|
| Risk Factors | 2 | 2019 | 3596 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 673 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 375 | 0.080 |
Why?
|
| Cyclosporine | 3 | 2015 | 34 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 2013 | 496 | 0.080 |
Why?
|
| United States | 3 | 2018 | 3685 | 0.080 |
Why?
|
| Disease Models, Animal | 3 | 2020 | 983 | 0.080 |
Why?
|
| Gene Expression | 2 | 2020 | 334 | 0.080 |
Why?
|
| Middle Aged | 7 | 2018 | 10920 | 0.080 |
Why?
|
| Recovery of Function | 1 | 2008 | 190 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 3 | 2016 | 713 | 0.070 |
Why?
|
| Cell Line | 2 | 2011 | 455 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 197 | 0.070 |
Why?
|
| Surgery, Plastic | 1 | 2007 | 26 | 0.070 |
Why?
|
| Collagen | 2 | 2018 | 218 | 0.070 |
Why?
|
| T-Lymphocytes | 3 | 2019 | 116 | 0.070 |
Why?
|
| Biocompatible Materials | 2 | 2019 | 212 | 0.070 |
Why?
|
| Interprofessional Relations | 1 | 2007 | 48 | 0.070 |
Why?
|
| Young Adult | 4 | 2018 | 2423 | 0.070 |
Why?
|
| Epitopes | 2 | 2020 | 21 | 0.070 |
Why?
|
| Drug Therapy, Combination | 3 | 2003 | 273 | 0.070 |
Why?
|
| Quality of Life | 1 | 2012 | 828 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2020 | 183 | 0.070 |
Why?
|
| Preoperative Care | 2 | 2019 | 110 | 0.060 |
Why?
|
| Austria | 2 | 2018 | 3 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 2121 | 0.060 |
Why?
|
| Hand | 3 | 2011 | 63 | 0.060 |
Why?
|
| Lymph Node Excision | 1 | 2004 | 89 | 0.060 |
Why?
|
| Histocompatibility Testing | 2 | 2016 | 15 | 0.060 |
Why?
|
| Thymus Gland | 1 | 2023 | 15 | 0.060 |
Why?
|
| Rats, Inbred F344 | 1 | 2003 | 125 | 0.060 |
Why?
|
| Prognosis | 2 | 2018 | 1369 | 0.050 |
Why?
|
| Chromatography, Liquid | 1 | 2022 | 42 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2013 | 126 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2023 | 95 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2022 | 57 | 0.050 |
Why?
|
| Collagen Type I | 1 | 2021 | 39 | 0.050 |
Why?
|
| Freund's Adjuvant | 1 | 2020 | 2 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2021 | 180 | 0.050 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2020 | 15 | 0.050 |
Why?
|
| Hydrocarbons, Cyclic | 1 | 2019 | 1 | 0.050 |
Why?
|
| Half-Life | 1 | 2019 | 22 | 0.040 |
Why?
|
| Dinoprostone | 1 | 2020 | 37 | 0.040 |
Why?
|
| Fluorocarbons | 1 | 2019 | 19 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2019 | 66 | 0.040 |
Why?
|
| Biological Transport | 1 | 2019 | 64 | 0.040 |
Why?
|
| Cyclooxygenase 2 | 1 | 2020 | 50 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2020 | 51 | 0.040 |
Why?
|
| Transplantation Conditioning | 2 | 2013 | 11 | 0.040 |
Why?
|
| Alginates | 1 | 2019 | 49 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 160 | 0.040 |
Why?
|
| Vasa Vasorum | 1 | 2019 | 1 | 0.040 |
Why?
|
| Corrosion | 1 | 2019 | 2 | 0.040 |
Why?
|
| Titanium | 1 | 2019 | 9 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2019 | 38 | 0.040 |
Why?
|
| Drug Implants | 1 | 2019 | 10 | 0.040 |
Why?
|
| Regional Blood Flow | 1 | 2019 | 82 | 0.040 |
Why?
|
| Knee | 1 | 2019 | 31 | 0.040 |
Why?
|
| Tunica Intima | 1 | 2019 | 59 | 0.040 |
Why?
|
| Terminology as Topic | 1 | 2019 | 63 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2020 | 167 | 0.040 |
Why?
|
| Replantation | 2 | 2011 | 9 | 0.040 |
Why?
|
| Materials Testing | 1 | 2019 | 84 | 0.040 |
Why?
|
| Femur | 1 | 2019 | 67 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 213 | 0.040 |
Why?
|
| Perfusion | 1 | 2018 | 64 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2018 | 37 | 0.040 |
Why?
|
| Intermediate Filaments | 1 | 2018 | 3 | 0.040 |
Why?
|
| GAP-43 Protein | 1 | 2018 | 6 | 0.040 |
Why?
|
| Myelin Sheath | 1 | 2018 | 6 | 0.040 |
Why?
|
| Penis | 1 | 2018 | 33 | 0.040 |
Why?
|
| Tensile Strength | 1 | 2018 | 52 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2017 | 3135 | 0.040 |
Why?
|
| Elastomers | 1 | 2017 | 1 | 0.040 |
Why?
|
| Chemokine CCL5 | 2 | 2011 | 6 | 0.040 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2018 | 71 | 0.040 |
Why?
|
| Uterus | 1 | 2018 | 74 | 0.040 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2018 | 74 | 0.040 |
Why?
|
| Lung | 1 | 2019 | 237 | 0.040 |
Why?
|
| Adolescent | 2 | 2018 | 3278 | 0.040 |
Why?
|
| Fetus | 1 | 2018 | 79 | 0.040 |
Why?
|
| Polyesters | 1 | 2017 | 72 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 638 | 0.040 |
Why?
|
| Calcium | 1 | 2019 | 301 | 0.040 |
Why?
|
| Computer-Aided Design | 1 | 2016 | 6 | 0.040 |
Why?
|
| Animals, Inbred Strains | 1 | 2016 | 1 | 0.040 |
Why?
|
| Equipment Failure Analysis | 1 | 2016 | 42 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 22 | 0.040 |
Why?
|
| Weight-Bearing | 1 | 2016 | 40 | 0.040 |
Why?
|
| Bone Regeneration | 1 | 2016 | 29 | 0.040 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2016 | 35 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2018 | 604 | 0.040 |
Why?
|
| Equipment Design | 1 | 2016 | 167 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 796 | 0.030 |
Why?
|
| Haplotypes | 1 | 2016 | 220 | 0.030 |
Why?
|
| Homeostasis | 1 | 2016 | 127 | 0.030 |
Why?
|
| B-Lymphocytes | 2 | 2008 | 71 | 0.030 |
Why?
|
| Plasmapheresis | 1 | 2015 | 9 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2015 | 21 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2015 | 35 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 60 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2015 | 76 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2015 | 48 | 0.030 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2015 | 4 | 0.030 |
Why?
|
| Granzymes | 1 | 2015 | 5 | 0.030 |
Why?
|
| Infant | 1 | 2018 | 975 | 0.030 |
Why?
|
| Immune System | 1 | 2015 | 8 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2015 | 84 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2015 | 26 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2018 | 1171 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 199 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 727 | 0.030 |
Why?
|
| Whole-Body Irradiation | 2 | 2004 | 48 | 0.030 |
Why?
|
| Mice, Inbred C3H | 1 | 2013 | 23 | 0.030 |
Why?
|
| Cell Transdifferentiation | 1 | 2013 | 6 | 0.030 |
Why?
|
| Phenylurea Compounds | 1 | 2013 | 11 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 438 | 0.030 |
Why?
|
| Mice, Inbred DBA | 1 | 2013 | 36 | 0.030 |
Why?
|
| Isoantigens | 1 | 2013 | 1 | 0.030 |
Why?
|
| Aminoquinolines | 1 | 2013 | 16 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2015 | 348 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2013 | 37 | 0.030 |
Why?
|
| Antilymphocyte Serum | 1 | 2013 | 17 | 0.030 |
Why?
|
| beta Catenin | 1 | 2013 | 37 | 0.030 |
Why?
|
| Disease Progression | 1 | 2015 | 574 | 0.030 |
Why?
|
| RNA Interference | 1 | 2013 | 76 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2013 | 62 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2013 | 172 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 109 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 249 | 0.030 |
Why?
|
| Fluid Therapy | 1 | 2012 | 27 | 0.030 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2012 | 1 | 0.030 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2012 | 1 | 0.030 |
Why?
|
| Heterocyclic Compounds | 1 | 2012 | 8 | 0.030 |
Why?
|
| Monitoring, Intraoperative | 1 | 2012 | 39 | 0.030 |
Why?
|
| Child | 1 | 2018 | 2228 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2012 | 25 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 483 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2012 | 74 | 0.030 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2011 | 13 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2011 | 15 | 0.030 |
Why?
|
| Antigens | 1 | 2011 | 31 | 0.030 |
Why?
|
| Acute Lung Injury | 1 | 2012 | 31 | 0.030 |
Why?
|
| Hemostasis, Surgical | 1 | 2011 | 13 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2011 | 23 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2011 | 62 | 0.030 |
Why?
|
| Extremities | 1 | 2011 | 48 | 0.030 |
Why?
|
| Demography | 1 | 2011 | 104 | 0.030 |
Why?
|
| Axons | 1 | 2011 | 24 | 0.030 |
Why?
|
| Nerve Fibers | 1 | 2011 | 31 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2011 | 47 | 0.020 |
Why?
|
| Cryopreservation | 1 | 2011 | 54 | 0.020 |
Why?
|
| Tendon Injuries | 1 | 2011 | 37 | 0.020 |
Why?
|
| Sciatic Nerve | 1 | 2011 | 35 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2013 | 520 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 162 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2013 | 438 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2011 | 225 | 0.020 |
Why?
|
| Anastomosis, Surgical | 1 | 2010 | 49 | 0.020 |
Why?
|
| Biological Products | 1 | 2011 | 66 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2015 | 2041 | 0.020 |
Why?
|
| Transplantation, Isogeneic | 1 | 2009 | 1 | 0.020 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2009 | 3 | 0.020 |
Why?
|
| Vascular Surgical Procedures | 1 | 2010 | 91 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 520 | 0.020 |
Why?
|
| Musculoskeletal Abnormalities | 1 | 2009 | 1 | 0.020 |
Why?
|
| Spain | 1 | 2009 | 3 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2009 | 59 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2009 | 49 | 0.020 |
Why?
|
| Amputation | 1 | 2009 | 37 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2008 | 100 | 0.020 |
Why?
|
| Occupational Therapy | 1 | 2007 | 3 | 0.020 |
Why?
|
| Psychiatry | 1 | 2007 | 13 | 0.020 |
Why?
|
| Registries | 1 | 2007 | 280 | 0.020 |
Why?
|
| Aged | 1 | 2018 | 9572 | 0.020 |
Why?
|
| Chimera | 1 | 2004 | 8 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2004 | 23 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2004 | 55 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 1 | 2003 | 15 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2002 | 51 | 0.010 |
Why?
|
| Public Opinion | 1 | 2002 | 17 | 0.010 |
Why?
|
| Binding Sites | 1 | 2002 | 125 | 0.010 |
Why?
|
| Heparin | 1 | 2002 | 75 | 0.010 |
Why?
|
| Forecasting | 1 | 2002 | 133 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2002 | 150 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2002 | 241 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2002 | 163 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 299 | 0.010 |
Why?
|